Skip to main content
TipRanks
Go Ultimate75% OFF

Virax Biolabs Group Ltd. Class A (VRAX) Ratios

170 Followers

Virax Biolabs Group Ltd. Class A Ratios

VRAX's free cash flow for Q4 2026 was $-4.88M. For the 2026 fiscal year, VRAX's free cash flow was decreased by $-255.83K and operating cash flow was $-4.62M. See a summary of the company’s cash flow.

Financial ratios
RatiosMar 26Mar 25Mar 24Mar 23Sep 22
Liquidity Ratios
Current Ratio9.977.2725.9410.610.04
Quick Ratio9.907.1325.5810.580.02
Cash Ratio9.406.2821.2610.300.02
Solvency Ratio-4.63-5.93-19.21-6.010.02
Operating Cash Flow Ratio-6.75-6.78-37.00-4.60-0.65
Short-Term Operating Cash Flow Coverage-162.30-140.560.00-28.580.00
Net Current Asset Value$ 5.84M$ 3.93M$ 4.04M$ 8.73M$ -1.20M
Leverage Ratios
Debt-to-Assets Ratio0.050.060.040.010.08
Debt-to-Equity Ratio0.050.070.040.02-0.00
Debt-to-Capital Ratio0.050.060.040.02-0.00
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.101.131.021.08-0.05
Debt Service Coverage Ratio-50.21-62.50-245.89-33.65-0.05
Interest Coverage Ratio-103.60-105.93-241.70-370.62-112.30
Debt to Market Cap0.010.010.000.020.00
Interest Debt Per Share1.203.510.130.150.02
Net Debt to EBITDA1.110.660.511.6924.00
Profitability Margins
Gross Profit Margin61.90%-838.21%32.34%-15.94%0.00%
EBIT Margin-47256.31%-97073.35%-4291.19%-63570.74%0.00%
EBITDA Margin-43722.40%-91649.46%-4225.28%-63570.74%0.00%
Operating Profit Margin-51515.17%-97344.76%-4153.25%-66963.67%0.00%
Pretax Profit Margin-47753.55%-97992.31%-4308.38%-63751.47%0.00%
Net Profit Margin-40439.10%-95739.17%-4304.81%-63748.32%0.00%
Continuous Operations Profit Margin-40507.00%-95833.71%-4308.38%-63751.47%0.00%
Net Income Per EBT84.68%97.70%99.92%100.00%97.65%
EBT Per EBIT92.70%100.67%103.74%95.20%100.93%
Return on Assets (ROA)-60.35%-94.31%-122.79%-55.62%-3508.45%
Return on Equity (ROE)-66.30%-106.41%-125.47%-59.80%175.34%
Return on Capital Employed (ROCE)-83.77%-107.11%-122.23%-64.38%144.87%
Return on Invested Capital (ROIC)-70.05%-103.22%-121.13%-63.34%144.87%
Return on Tangible Assets-60.35%-94.90%-123.91%-56.65%-3508.45%
Earnings Yield-229.74%-171.67%-456.60%-73.83%-0.83%
Efficiency Ratios
Receivables Turnover0.000.210.720.000.00
Payables Turnover0.091.062.320.060.00
Inventory Turnover0.100.631.750.410.00
Fixed Asset Turnover0.010.000.140.000.00
Asset Turnover0.000.000.030.000.00
Working Capital Turnover Ratio0.000.000.020.000.00
Cash Conversion Cycle-287.192004.38559.21-4994.130.00
Days of Sales Outstanding0.001767.29508.330.000.00
Days of Inventory Outstanding3704.91581.78208.26886.020.00
Days of Payables Outstanding3992.10344.69157.385880.160.00
Operating Cycle3704.912349.07716.59886.020.00
Cash Flow Ratios
Operating Cash Flow Per Share-11.62-36.84-3.11-3.93-0.71
Free Cash Flow Per Share-12.27-41.71-3.69-4.10-0.71
Dividend Paid and CapEx Coverage Ratio-18.07-7.56-5.36-23.430.00
Capital Expenditure Coverage Ratio-18.07-7.56-5.36-23.430.00
Operating Cash Flow Coverage Ratio-11.15-12.10-27.85-28.58-215.29
Operating Cash Flow to Sales Ratio-372.04-720.83-39.94-488.230.00
Free Cash Flow Yield-223.06%-146.36%-502.57%-58.96%-0.39%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-0.44-0.58-0.22-1.35-121.14
Price-to-Sales (P/S) Ratio176.02557.689.43863.450.00
Price-to-Book (P/B) Ratio0.290.620.270.81-212.41
Price-to-Free Cash Flow (P/FCF) Ratio-0.45-0.68-0.20-1.70-255.86
Price-to-Operating Cash Flow Ratio-0.47-0.77-0.24-1.77-255.86
Price-to-Earnings Growth (PEG) Ratio0.010.010.01-0.01-0.74
Enterprise Value Multiple0.710.060.290.33-275987.25
Enterprise Value-3.84M-321.25K-1.89M-1.81M206.99M
EV to EBITDA0.710.060.290.33-275987.25
EV to Sales-308.93-50.74-12.08-211.930.00
EV to Free Cash Flow0.790.060.260.42-255.84
EV to Operating Cash Flow0.830.070.300.43-255.84
Tangible Book Value Per Share18.4543.772.548.21-1.05
Shareholders’ Equity Per Share19.0645.982.678.59-0.86
Tax and Other Ratios
Effective Tax Rate0.150.020.000.000.00
Revenue Per Share0.030.050.080.010.00
Net Income Per Share-12.64-48.93-3.36-5.13-1.50
Tax Burden0.850.981.001.000.98
Interest Burden1.011.011.001.001.01
Research & Development to Revenue300.92281.129.9946.390.00
SG&A to Revenue214.85683.9429.37619.980.00
Stock-Based Compensation to Revenue10.5057.706.47202.620.00
Income Quality0.920.750.930.770.47

Currency in USD